Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Arena Pharmaceuticals, Inc.    ARNA

Delayed Quote. Delayed  - 07/26 10:00:00 pm
1.67 USD   +0.60%
07/19 EISAI : Inc. and Arena Pharmaceuticals Announce FDA Approval of BELV..
07/14 ARENA PHARMACEU : Eisai and Arena Pharmaceuticals Announce Regulator..
06/30 ARENA PHARMACEU : Announces Shift to Focus on Proprietary Clinical S..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector news 
Most relevant news about ARENA PHARMACEUTICALS, INC
07/19 EISAI : Inc. and Arena Pharmaceuticals Announce FDA Approval of BELVIQ XR® (lorc..
07/14 ARENA PHARMACEUTICALS : Eisai and Arena Pharmaceuticals Announce Regulatory Appr..
06/30 ARENA PHARMACEUTICALS : Announces Shift to Focus on Proprietary Clinical Stage P..
06/16 ARENA PHARMACEUTICALS : Announces Appointment of Kevin R. Lind as Chief Financia..
06/15 ARENA PHARMACEUTICALS : Announces Appointment of Kevin R. Lind as Chief Financia..
06/13 ARENA PHARMACEUTICALS : Announces USAN Approval of Nonproprietary Name "Etrasimo..
05/09 ARENA PHARMACEUTICALS : reports 1Q loss
05/09 ARENA PHARMACEUTICALS : Announces Appointment of Amit D. Munshi as President and..
05/09 ARENA PHARMACEUTICALS : Reports First Quarter 2016 Financial Results and Provide..
05/02 ARENA PHARMACEUTICALS : to Host First Quarter 2016 Financial Results and Corpora..
04/16 ARENA PHARMACEUTICALS : Perrigo Firm, Arena Pharmaceuticals, Actinium Pharmaceut..
04/13 ARENA PHARMACEUTICALS' : APD371 pain drug succeeds in early-stage test
04/12 ARENA PHARMACEUTICALS : Reports Favorable Results from Phase 1b Multiple-Ascendi..
02/29 ARENA PHARMACEUTICALS : reports 4Q loss
02/29 ARENA PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2015 Financial Resu..
More most relevant news
All news about ARENA PHARMACEUTICALS, INC
07/19 ARENA PHARMACEUTICALS INC : Other Events (form 8-K)
07/19 EISAI : Inc. and Arena Pharmaceuticals Announce FDA Approval of BELVIQ XR® (lorc..
07/14 ARENA PHARMACEUTICALS : Eisai and Arena Pharmaceuticals Announce Regulatory Appr..
07/07 ARENA PHARMACEUTICALS : Announces Shift to Focus on Proprietary Clinical Stage P..
06/30 ARENA PHARMACEUTICALS INC : Costs Associated with Exit or Disposal Activities (f..
06/30 ARENA PHARMACEUTICALS : Announces Shift to Focus on Proprietary Clinical Stage P..
06/23 ARENA PHARMACEUTICALS : Announces USAN Approval of Nonproprietary Name "Etrasimo..
06/23 ARENA PHARMACEUTICALS : Announces Appointment of Kevin R. Lind as Chief Financia..
06/16 ARENA PHARMACEUTICALS : Announces Appointment of Kevin R. Lind as Chief Financia..
06/16 ARENA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial..
More news
Sector news : Biotechnology & Medical Research - NEC
01:22p GSK chases next biotech asthma drug with 175 million pounds J&J deal
07/26 GILEAD SCIENCES : cuts 2016 sales forecast, cites hepatitis C drugs
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 2nd Update
07/25DJCELGENE : Drug Misses Secondary Endpoint in One of Its Lymphoma Trials
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 3rd Update
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
07/21 The End Of Another Chapter In Obesity Drug Development
07/20 Vivus Begins Q3 With Underwhelming Qsymia Sales
07/20 What Arena's Recent FDA Approval Means For The Future
07/20 Orexigen - Contrave Scripts Nosedive With Holiday Week - Downward Pressure Ta..
07/19 Arena - Belviq Scripts Start Q3 In Tough Shape
07/19 Arena Banks $10 Million On FDA Approval For New Belviq Formulation - What It ..


Advertisement
Financials ($)
Sales 2016 48,7 M
EBIT 2016 -79,7 M
Net income 2016 -83,1 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 8,33x
Capi. / Sales 2017 6,02x
Capitalization 406 M
More Financials
Chart ARENA PHARMACEUTICALS, INC
Duration : Period :
Arena Pharmaceuticals, Inc Technical Analysis Chart | ARNA | US0400471027 | 4-Traders
Full-screen chart
Technical analysis trends ARENA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Average target price 3,75 $
Spread / Average Target 125%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Amit D. Munshi President, Chief Executive Officer & Director
Craig M. Audet SVP-Operations & Head-Global Regulatory Affairs
Kevin R. Lind Chief Financial Officer & Executive Vice President
Dominic P. Behan Executive Director, Chief Scientific Officer & EVP
Donald D. Belcher Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ARENA PHARMACEUTICALS,..-12.11%406
INCYTE CORPORATION-19.82%16 315
CELLTRION, INC.--.--%10 696
LONZA GROUP AG11.40%9 743
QUINTILES TRANSNATIONA..9.89%9 029
ALKERMES PLC-35.74%7 711
More Results